Employees: 2,831
Size Aarti Drugs (AARTIDRUGS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $494M, the 846th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹505.75 on 18 Nov 2026.
Performance Over six months the shares gained 33.7%, against -18.4% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 15.1% over the last twelve months (peer median +9.8%); the operating margin is 10.9% (peer median 10.0%).
Valuation It trades at 21.3× forward earnings against a peer median of 15.1× (2nd most expensive of 6).
Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.2 points below its cost of capital (13.4% WACC).
Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹28.5B | ₹25.6B | ₹23.8B | ₹25.2B | ₹27.2B |
| Revenue growth | — | +7% | -6% | -7% | — |
| Gross profit | ₹8.75B | ₹3.72B | ₹3.46B | ₹3.64B | ₹3.69B |
| EBITDA | ₹3.84B | ₹3.06B | ₹2.87B | ₹3.20B | ₹3.15B |
| Net income | ₹2.29B | ₹1.95B | ₹1.68B | ₹1.71B | ₹1.66B |
| Free cash flow | n/a | ₹491M | ₹462M | ₹1.04B | -₹661M |
| Capital expenditure | n/a | ₹1.73B | ₹1.77B | ₹2.26B | ₹1.65B |
| Total debt | ₹6.20B | ₹5.77B | ₹6.15B | ₹5.64B | ₹6.09B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AARTIDRUGS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.7% | -2.1% | highest of 21 |
| 6-month return | +33.7% | -18.4% | 5th highest of 21 |
| Distance from 52-week high | -4.1% | -35.5% | 2nd highest of 21 |
| Revenue growth (TTM) | +15.1% | +9.8% | 7th highest of 20 |
| Operating margin | 10.9% | 10.0% | 10th highest of 20 |
| Forward P/E | 21.3× | 15.1× | 2nd most expensive of 6 |
| Growth the price implies (Req g, 7 yrs) | 22.1% | -0.7% | most demanding of 9 |
| Growth delivered (Del g) | +3.5% | +7.0% | 3rd lowest of 9 |
| Hurdle (Req g minus delivered) | +18.6 pp | -6.6 pp | most demanding of 9 |
| ROIC minus cost of capital | -3.2 pp | -2.4 pp | 8th lowest of 18 |
| EV / EBITDA | 13.6× | 15.3× | 3rd cheapest of 5 |
| Net debt / EBITDA | 1.6× | 1.8× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 21.3× | 22.1% | +3.5% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | n/a | 5.9% | -4.1% |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 4.1× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | n/a | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | n/a | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 7.3× | -17.2% | +6.3% |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | n/a | 16.7% | +4.4% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 18.2× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | n/a | -5.4% | +7.6% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | n/a | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | n/a | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | n/a | -4.7% | +105.3% |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 15.1× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | n/a | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 42.2× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | n/a | -6.1% | +9.6% |